Patient Lifetime Value in Peptide Therapy: $8,400 Average (Here's Why)

The average patient lifetime value (LTV) in peptide therapy is $8,400. That figure comes from an average monthly spend of $700 per patient — covering consultations, peptide compounds, lab work, and ancillary products — multiplied by an average retention period of 12 months. But the $8,400 figure is just the midpoint. Single-protocol BPC-157 patients average $4,800–$6,000, while multi-protocol patients on stacked peptide regimens routinely reach $12,000–$18,000 in lifetime value. The difference between the low end and the high end is not luck. It is the result of specific operational decisions: how you onboard, how you bill, how often you follow up, and whether your technology helps or hinders all three.

The $8,400 Breakdown

Patient lifetime value is not a vanity metric. It is the single number that determines whether your practice economics work: how much you can afford to spend on acquisition, how aggressively you can invest in staff and technology, and whether your clinic builds compounding value over time or bleeds patients faster than it replaces them.

The $8,400 average LTV in peptide therapy breaks down across three components:

What Makes Up the $700 Monthly Spend

The $700 average monthly spend is not a single line item. It is a composite of several revenue streams that a well-run peptide therapy practice generates from each active patient:

Peptide compounds are the largest single component, but they are also the most variable. A patient on BPC-157 alone may spend $200–$300 per month on compounds, while a patient on Sermorelin plus CJC-1295/Ipamorelin may spend $400–$600. The consultation and lab revenue layers are what stabilize the average and create predictable recurring revenue regardless of protocol mix.

The 12-Month Retention Window

Twelve months is the industry median, not the mode. The retention curve in peptide therapy is heavily front-loaded with churn:

• Months 1–3: 25% of patients discontinue. The primary drivers are unmet expectations, side effects that are not proactively managed, and sticker shock from the first recurring charge.
• Months 4–6: An additional 15% discontinue. This phase is driven by perceived plateaus in results and the "novelty wearing off" effect.
• Months 7–12: Churn drops to 3–5% per month. Patients who reach the 6-month mark have typically experienced meaningful clinical outcomes and have integrated their protocol into their routine.
• Months 13+: 35–40% of patients who reach 6 months continue for 24 months or longer. These are your highest-value patients, and they are also the most likely to add protocols and refer others.

Protocol Expansion Over Time

Patient spending does not remain static over the 12-month average. In well-managed practices, monthly revenue per patient increases over time as patients add protocols, agree to more frequent lab monitoring, and purchase ancillary products. The typical expansion pattern looks like this:

• Months 1–3: $500–$600/month. Patient is on a single introductory protocol. Consultations are more frequent (initial titration).
• Months 4–8: $650–$750/month. First protocol expansion typically occurs here. Patients who see results on BPC-157 often add a GH secretagogue or NAD+ protocol.
• Months 9–12+: $800–$1,000/month. Multi-protocol patients settle into their full regimen. Lab monitoring becomes quarterly. Supplement orders become consistent.

This expansion curve means the back half of the patient lifecycle is disproportionately valuable. Losing a patient at month 3 costs you $1,800 in realized revenue. Losing a patient at month 10 costs you $7,500 — but more importantly, it costs you the $1,000+ per month they would have spent in months 13 through 24.

LTV by Protocol Type

Not all peptide therapy patients are created equal from a lifetime value perspective. The protocol a patient starts on is the single strongest predictor of their eventual LTV, because it determines their monthly spend, their clinical engagement level, and their likelihood of expanding to additional protocols.

BPC-157: Lower LTV, Higher Volume

BPC-157 patients are typically seeking injury recovery or gut healing — conditions with a perceived endpoint. This creates natural attrition as patients feel their issue is resolved. Average retention is 10–12 months, and monthly spend is lower because the protocol itself is less expensive than GH secretagogues. However, BPC-157 patients are often the highest-volume entry point for peptide clinics. They convert from CRM lead pipelines at higher rates because the use case is concrete and immediate. The strategic play is converting BPC-157 patients into multi-protocol patients once their initial condition resolves.

Sermorelin and GH Peptides: The LTV Sweet Spot

Patients on growth hormone secretagogue protocols (Sermorelin, CJC-1295/Ipamorelin, Tesamorelin) represent the LTV sweet spot at $7,200–$9,600. These protocols address anti-aging, body composition, and sleep quality — ongoing concerns without a clear endpoint. Monthly spend is higher due to compound costs, and retention is longer because results are cumulative and progressive. GH peptide patients are also the most likely to add complementary protocols (NAD+, BPC-157 for acute issues) because they are already invested in an optimization mindset.

NAD+ Therapy: High Margins, Moderate Retention

NAD+ patients fall in the middle tier at $6,000–$8,400 LTV. The protocol carries higher margins for the clinic (NAD+ compounds have strong markup potential), but retention is slightly lower than GH peptides because the subjective benefits (energy, cognitive clarity) can be harder for patients to attribute specifically to the protocol versus lifestyle changes they may be making simultaneously. Clinics that pair NAD+ with regular biomarker tracking to demonstrate objective improvements see 20–30% better retention in this cohort.

Multi-Protocol Patients: The 2–3x Multiplier

Multi-protocol patients are the most valuable cohort in any peptide therapy practice, with LTV of $12,000–$18,000. They spend 60–80% more per month than single-protocol patients, and they retain for 50–100% longer. The compounding effect of higher spend multiplied by longer retention is what creates the 2–3x LTV multiplier.

Multi-protocol patients also generate disproportionate referral value. They are more engaged with their provider, more likely to share their experience with peers, and more likely to refer high-value prospects who are also interested in multi-protocol regimens. We will cover referral dynamics in detail in the factors that increase LTV section below.

Factors That Increase LTV

LTV is not fixed at the point of patient acquisition. It is shaped by operational decisions that compound over the patient lifecycle. The five highest-impact levers, ranked by magnitude of effect:

1. Protocol Stacking

Patients on two or more concurrent protocols spend 60–80% more per month and retain 50–100% longer than single-protocol patients. This is the single largest LTV lever. The key operational requirement is a clinical workflow that systematically identifies protocol expansion opportunities at each follow-up visit. This means your prescribing workflow must surface relevant protocol recommendations based on the patient's current regimen, lab results, and stated goals.

2. Annual Lab Monitoring Programs

Structured lab monitoring serves two purposes: it generates $800–$1,600 per patient per year in direct revenue (from quarterly panels at $200–$400 each), and it improves retention by giving patients objective evidence that their protocols are working. Labs are also the most natural protocol expansion trigger — when bloodwork reveals an optimization opportunity, the clinical conversation about adding a protocol is evidence-based rather than salesy.

Clinics with integrated lab ordering and results delivery see 23% higher lab completion rates than those using manual processes, which directly translates to both lab revenue and retention improvements.

3. Subscription Billing Models

Subscription billing increases retention by 35–45% compared to pay-per-visit or manual invoicing models. The mechanism is behavioral: subscription patients make one payment decision (to subscribe) rather than a payment decision every month (to reorder). Each payment decision point is a potential exit point. Removing friction removes exits.

Beyond retention, subscription billing also increases average monthly spend by 12–18% because patients can be enrolled in bundled plans that include consultation, compounds, and labs at a package price that is higher than what they would spend a la carte but feels like better value.

4. Supplement and Ancillary Add-Ons

Supplement sales add $50–$75 per month per patient on average, but their LTV impact extends beyond the direct revenue. Patients who purchase supplements through your clinic have a 28% lower churn rate than those who do not, likely because each supplement order is an additional touchpoint and commitment. The e-commerce infrastructure required to sell supplements profitably is the same infrastructure you need for compound sales, so the marginal cost of adding a supplement line is low.

5. Referral Programs

Referred patients have 37% higher LTV than patients acquired through paid advertising. They arrive with higher trust (pre-sold by someone they know), are more likely to follow through on protocol recommendations, and retain longer. A structured referral program that gives existing patients a meaningful incentive ($50–$100 credit per referral) can generate 15–25% of new patient volume at effectively zero CAC — the referral credit is paid from existing patient LTV, not from marketing budget.

Factors That Decrease LTV

Understanding what destroys LTV is as important as understanding what builds it. These four failure modes account for the majority of preventable patient churn in peptide therapy practices:

1. Poor Onboarding

The first 14 days after a patient starts a peptide protocol are the highest-risk period for dropout. Patients who do not receive structured onboarding — including clear dosing instructions, realistic timeline expectations, proactive check-in at day 7, and a follow-up appointment before day 30 — churn at 2.5x the rate of patients who do. Poor onboarding is the number one destroyer of LTV because it operates at the top of the funnel: every patient lost in onboarding was acquired at full CAC but generated near-zero revenue.

A complete onboarding framework is covered in our patient onboarding guide.

2. Billing Friction

Manual invoicing, unclear pricing, surprise charges, and failed payment recovery all create friction that pushes patients toward the exit. The most damaging billing failure is the involuntary churn caused by expired credit cards and failed automatic payments. Without automated dunning sequences (a series of retry attempts and notifications), 8–12% of subscription patients are lost each year to payment failures that are entirely recoverable. At $8,400 LTV per patient, each unrecovered payment failure costs the practice more than the entire annual cost of a billing automation system.

3. Lack of Follow-Up

Peptide therapy patients who go more than 45 days without a provider touchpoint are 3x more likely to discontinue than those with regular contact. "Follow-up" does not need to mean a full consultation every month — it can be an automated check-in message, a lab result review, or even a protocol adherence reminder. The point is that silence from the clinic signals to the patient that their care is transactional rather than relational. Patients who feel managed rather than cared for will eventually find a reason to stop.

4. Side Effect Management Gaps

Peptide protocols can produce side effects — injection site reactions, water retention, fatigue during GH secretagogue titration — that are clinically minor but psychologically significant to patients. When patients experience side effects and do not have a fast, clear channel to report them and receive reassurance or dose adjustment, they often discontinue the protocol entirely rather than reaching out. This is a communication infrastructure problem, not a clinical one. Clinics with HIPAA-compliant asynchronous messaging see 40% fewer side-effect-driven discontinuations than those relying on phone calls and scheduled appointments for side effect management.

LTV:CAC Ratio Analysis

Patient lifetime value becomes actionable when measured against patient acquisition cost (CAC). The LTV:CAC ratio tells you whether your practice economics are sustainable, how much you can afford to invest in growth, and where the floor is on your marketing efficiency.

What Each Ratio Means

• Below 3:1 — Your practice is spending too much to acquire patients relative to what they generate. This is a red flag that requires immediate attention to either acquisition costs or retention.
• 3:1 to 5:1 — Viable but tight. You have limited margin for growth investment, and a small increase in churn or CAC could push you below breakeven on marketing spend.
• 5:1 to 8:1 — Healthy. You have room to invest in growth, hire staff, and upgrade technology while maintaining profitability. This is the target range for scaling practices.
• 8:1 to 15:1 — Strong. Typically achieved by practices with mature referral programs, strong organic search presence, and low churn. At this level, the question is whether you are underinvesting in growth.
• Above 15:1 — Exceptional, but verify you are not underinvesting in acquisition. A very high ratio can mean you are leaving growth on the table by not spending enough on marketing.

Typical CAC by Channel

The critical insight from this table: even the most expensive digital acquisition channels produce acceptable LTV:CAC ratios at the $8,400 average LTV. The $8,400 figure gives peptide therapy practices significant marketing flexibility. The question is not whether you can afford to acquire patients — it is which channels produce the highest-quality patients (measured by retention and protocol expansion, not just initial conversion).

How Technology Impacts LTV

Technology does not generate LTV directly. It operates on LTV indirectly through three mechanisms: reducing friction that causes churn, automating retention activities that would otherwise depend on staff memory and discipline, and surfacing data that enables smarter clinical and business decisions. The practices with the highest patient LTV are not necessarily the ones with the best providers — they are the ones with systems that prevent the operational failures that destroy value.

Automated Follow-Up Sequences

Automated follow-up is the single highest-ROI technology investment for LTV improvement. A well-designed follow-up system sends protocol-specific check-ins at clinically relevant intervals (day 7 for injection site reaction screening, day 14 for early efficacy assessment, day 30 for first formal follow-up scheduling, then monthly thereafter). Practices using automated follow-up see 35–40% lower churn in the first 90 days compared to those relying on manual outreach.

The cost of automated follow-up via a purpose-built platform is a rounding error relative to the LTV it preserves. Losing one patient per month to preventable churn costs $8,400 in LTV. An automated system that prevents even a fraction of those losses pays for itself many times over. Our analysis of peptide clinic technology costs breaks down the full stack economics.

Subscription Billing and Dunning Automation

Subscription billing impacts LTV through two channels: it increases voluntary retention (by removing monthly payment decisions) and it reduces involuntary churn (through automated payment retry and dunning sequences). The combined effect is a 35–45% retention improvement.

Automated dunning alone recovers 28% of failed payments that would otherwise result in patient loss. For a practice with 200 active patients on subscription billing, preventing even 5 involuntary cancellations per year preserves $42,000 in LTV — from a feature that requires zero ongoing staff effort once configured.

Patient Portal Engagement

Patient portals create a persistent, measurable connection between the patient and the practice. Patients who log in to their portal at least once per week have 2.3x higher retention than patients who never use their portal. The portal serves as a daily reminder that the patient is an active member of a clinical program, not a one-time customer of a transactional service.

Key portal engagement drivers that correlate with higher LTV:

• Lab result delivery through the portal (instead of phone or email) — drives an average of 4.2 portal visits per quarter
• Secure messaging with providers — patients who message their provider at least once per month have 45% higher retention
• Prescription and supplement reorder functionality — each reorder is both a revenue event and an engagement touchpoint
• Progress tracking dashboards — visual evidence of improvement reinforces the value of continued treatment

The portal requirements for peptide therapy clinics differ from general telehealth — see our HIPAA-compliant patient portal guide for the full specification.

CRM and Lead Pipeline Management

Your CRM impacts LTV before the patient even starts treatment. Leads that are nurtured through a structured CRM pipeline convert to patients with 22% higher 12-month retention than leads that convert through ad-hoc outreach. The reason: a CRM pipeline allows you to qualify leads on commitment level, set expectations before the first visit, and match incoming patients to the protocols where they are most likely to succeed (and retain).

CRM also enables the referral tracking required to measure referral program ROI and identify your highest-value referral sources — data that directly informs LTV optimization.

Cohort Analysis: Tracking and Improving LTV

A single average LTV number is useful for planning. A cohort-level LTV analysis is useful for improvement. Cohort analysis groups patients by the month they started treatment and tracks each group's cumulative revenue, retention, and expansion rate over time. This reveals whether your practice is getting better or worse at retaining and growing patients, and it isolates the impact of specific operational changes.

How to Set Up Cohort Tracking

At minimum, you need to track four metrics for each monthly cohort:

1. Cohort size — How many patients started in this month.
2. Retention rate by month — What percentage of the cohort is still active at month 1, 2, 3, etc.
3. ARPU by month — Average revenue per patient in the cohort at each month mark. This captures protocol expansion.
4. Cumulative LTV — Total revenue generated by the cohort divided by cohort size. This is the running LTV figure.

Cohort Benchmarks for Peptide Therapy

Using Cohort Data to Prioritize Investments

Cohort analysis turns LTV optimization from guesswork into a capital allocation exercise. If your cohort data shows that month-3 retention is your weakest metric relative to benchmarks, invest in onboarding. If month-3 retention is strong but protocol expansion rate is low, invest in clinical workflow tools that surface expansion opportunities. If both retention and expansion are strong but CAC is high, invest in referral programs and organic content to bring down blended acquisition cost.

The practices that achieve top-quartile LTV are not doing everything well — they are using cohort data to identify and fix their specific weakest link in the patient value chain. The technology stack implications of this approach are covered in detail in our technology cost breakdown.

LTV Improvement Roadmap by Practice Stage

Frequently Asked Questions